Case-Control Exploration of Relationships Between Early Rash or Liver Toxicity and Plasma Concentrations of Nevirapine and Primary Metabolites
- 1 December 2007
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 8 (6), 391-399
- https://doi.org/10.1310/hct0806-391
Abstract
Objective: This investigation measured trough nevirapine and five oxidative metabolite concentrations in plasma specimens collected from patients who exhibited a rash or liver function abnormality during the first 6 weeks of treatment. Method: Patient selection came from three clinical trials, totaling 1,357 patients, from which frozen specimens had been stored and were available for assay. The control patients were matched according to trial, steroid use, CD4 cell count, gender, race, and hepatitis B/C status. Observed plasma metabolite concentrations were compared using signed rank tests. Results: A total of 49 case-control pairs were studied. Women had significantly greater exposure than men to nevirapine and four of the five metabolites at week 2, but the plasma concentrations were comparable by week 4. Steroid (prednisone) co-medication produced significantly different plasma nevirapine and metabolite concentrations for the majority of case-control comparisons at week 3, a week after cessation of steroid treatment, but only occasionally produced a measurable difference at other weeks. Conclusion: During the first 6 weeks of nevirapine therapy, the rashes and liver enzyme elevations that occurred appear to be idiosyncratic. There were no strong relationships observed between the plasma concentrations of nevirapine or any of its five metabolites to a casedefining event. The systemic exposure of the metabolite 12-hydroxynevirapine and its successor 4-carboxynevirapine, hypothesized in the skin rash female Brown Norway rat model as reactive intermediates for idiosyncratic immune-mediated adverse reactions, were comparable between case and control samples and were comparable in proportion to the precursor nevirapine exposure. PDF Keywords liver, nevirapine, nevirapine oxidative metabolites, rash Related articles View all related articles var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; var addthis_config = {"data_track_addressbar":true,"ui_click":true}; Add to shortlist Link Permalink http://dx.doi.org/10.1310/hct0806-391 Download Citation Recommend to: A friendKeywords
This publication has 8 references indexed in Scilit:
- Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2007
- Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN StudyHIV Research & Clinical Practice, 2005
- Defining the Toxicity Profile of Nevirapine and Other Antiretroviral DrugsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Characterization of a Potential Animal Model of an Idiosyncratic Drug Reaction: Nevirapine-Induced Skin Rash in the RatChemical Research in Toxicology, 2003
- Randomized, Controlled Study of the Effects of a Short Course of Prednisone on the Incidence of Rash Associated With Nevirapine in Patients Infected With HIV-1JAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Synthesis of five nevirapine metabolitesJournal of Heterocyclic Chemistry, 2000
- Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathwaysClinical Pharmacology & Therapeutics, 1999
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998